Abstract

Background18F-THK5351 is a quinoline-derived tau imaging agent with high affinity to paired helical filaments (PHF). However, high levels of 18F-THK5351 retention in brain regions thought to contain negligible concentrations of PHF raise questions about the interpretation of the positron emission tomography (PET) signals, particularly given previously described interactions between quinolone derivatives and monoamine oxidase B (MAO-B). Here, we tested the effects of MAO-B inhibition on 18F-THK5351 brain uptake using PET and autoradiography.MethodsEight participants (five mild cognitive impairment, two Alzheimer’s disease, and one progressive supranuclear palsy) had baseline 18F-AZD4694 and 18F-THK5351 scans in order to quantify brain amyloid and PHF load, respectively. A second 18F-THK5351 scan was conducted 1 week later, 1 h after a 10-mg oral dose of selegiline. Three out of eight patients also had a third 18F-THK5351 scan 9–28 days after the selegiline administration. The primary outcome measure was standardized uptake value (SUV), calculated using tissue radioactivity concentration from 50 to 70 min after 18F-THK5351 injection, normalizing for body weight and injected radioactivity. The SUV ratio (SUVR) was determined using the cerebellar cortex as the reference region. 18F-THK5351 competition autoradiography studies in postmortem tissue were conducted using 150 and 500 nM selegiline.ResultsAt baseline, 18F-THK5351 SUVs were highest in the basal ganglia (0.64 ± 0.11) and thalamus (0.62 ± 0.14). In the post-selegiline scans, the regional SUVs were reduced on average by 36.7% to 51.8%, with the greatest reduction noted in the thalamus (51.8%) and basal ganglia (51.4%). MAO-B inhibition also reduced 18F-THK5351 SUVs in the cerebellar cortex (41.6%). The SUVs remained reduced in the three patients imaged at 9–28 days. Tissue autoradiography confirmed the effects of MAO-B inhibition on 18F-THK5351 uptake.ConclusionsThese results indicate that the interpretation of 18F-THK5351 PET images, with respect to tau, is confounded by the high MAO-B availability across the entire brain. In addition, the heterogeneous MAO-B availability across the cortex may limit the interpretation of 18F-THK5351 scans using reference region methods.

Highlights

  • 18F-THK5351 is a quinoline-derived tau imaging agent with high affinity to paired helical filaments (PHF)

  • The standardized uptake value (SUV) reduction was greatest in the thalamus (51.8%), followed by the basal ganglia (51.4%)

  • SUVs decreased by approximately 30 to 50% depending on the brain region, with the highest decline noted in the basal ganglia and thalamus which are known to express the highest concentrations of monoamine oxidase (MAO)-B in the brain [4]

Read more

Summary

Introduction

18F-THK5351 is a quinoline-derived tau imaging agent with high affinity to paired helical filaments (PHF). High levels of 18F-THK5351 retention in brain regions thought to contain negligible concentrations of PHF raise questions about the interpretation of the positron emission tomography (PET) signals, given previously described interactions between quinolone derivatives and monoamine oxidase B (MAO-B). 18F-THK5351 is a quinoline-derivative tau imaging tracer with affinity to paired helical filaments (PHF), a typical tau aggregate present in neurofibrillary tangles (NFTs). Rather than PHF, the basal ganglia typically express high concentrations of aminergic projections, neuroreceptors, and their degrading enzymes such as monoamine oxidase (MAO) [4, 5]. It is plausible to hypothesize that MAOB (EC 1.4.3.4) constitutes a 18F-THK5351 off-target binding site, given its previous reported affinity to quinolone derivatives [6]. The presence of high concentrations of MAO-B in the human cortex demands a careful examination of the impact of MAO-B binding on 18F-THK5351 images

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call